A clinical trial published in 2022 found that an older GLP-1 drug called exenatide reduced drinking, but only among those who ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Depending on the medication, the effects can last for a minimum of 24 hours to a few weeks. Examples include dulaglutide, ...

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ...

1 A cohort of 227,886 individuals was followed from AUD diagnosis until death, emigration, or the study's end date, December ...

11月11日，争光股份涨1.97%，成交额4137.15万元，换手率3.81%，总市值33.94亿元。 根据AI大模型测算争光股份后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期该股有吸筹现象，但吸筹力度不强。舆情分析来看，目前市场情绪极度悲观。 异动分析 核污染防治+核电+超超临界发电+盐湖提锂+减肥药 1、2023年8月29 ...

However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

根据AI大模型测算争光股份后市走势。短期趋势看，连续2日被主力资金减仓。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期该股获筹码青睐，且集中度渐增。舆情分析来看，目前市场情绪极度悲观。